Puissance Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Puissance Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$11.7M	Hold	1,153,846	–	–	67.74%	1
2020 Q2	$14.5M	Buy	1,153,846 +600,596	+109%	+$8.4M	61.82%	1
2020 Q1	$6.06M	Hold	553,250	–	–	70.84%	1
2019 Q4	$2.9M	Hold	553,250	–	–	7.2%	3
2019 Q3	$4M	Hold	553,250	–	–	8.92%	4
2019 Q2	$4.97M	Hold	553,250	–	–	4.87%	4
2019 Q1	$5.42M	Hold	553,250	–	–	4.41%	5
2018 Q4	$6.65M	Hold	553,250	–	–	7.59%	4
2018 Q3	$8.96M	Hold	553,250	–	–	6.26%	5
2018 Q2	$20.1M	Hold	553,250	–	–	15.1%	3
2018 Q1	$17.3M	Hold	553,250	–	–	14.88%	3
2017 Q4	$21.4M	Buy	+553,250	New	+$14.5M	14.79%	3

Other funds holding BLPH

NMVA

New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Puissance Capital Management's BLPH Position: Q3 2020 in Review

Puissance Capital Management held its Bellerophon Therapeutics, Inc. (BLPH) position steady in Q3 2020 at 1,153,846 shares worth $11.7M. The position accounts for 67.74% of the portfolio, ranked #1.

Puissance Capital Management first reported a position in BLPH in Q4 2017 and has held it in 12 quarters since. The position peaked at $21.4M in Q4 2017. 41 funds tracked by Wall St. Rank hold BLPH as of Q3 2020.

Puissance Capital Management held 1,153,846 shares of Bellerophon Therapeutics, Inc. worth $11.7M as of Q3 2020.
Puissance Capital Management left its Bellerophon Therapeutics, Inc. share count unchanged in Q3 2020.
Bellerophon Therapeutics, Inc. made up 67.74% of Puissance Capital Management's portfolio in Q3 2020, its #1 holding.
Puissance Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q4 2017 and has held it in 12 quarters since.
Puissance Capital Management's Bellerophon Therapeutics, Inc. position peaked at $21.4M in Q4 2017.
41 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q3 2020.

Based on Puissance Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.